DMK Pharmaceuticals Corporation was established on June 6, 2006 as a Delaware corporation. The company is an emerging pharmaceutical company that combines specialty pharmaceuticals and biotechnology to deliver innovative medicines to patients and physicians. The professional pharmaceutical products within the group mainly include some products under development in the allergy and respiratory markets, such as dry powder inhaler technology, which the company is currently applying for a special license and acquiring from 3M. The company's goal is to create low-cost treatments to replace existing treatments. 

DMK(Delisted)

DMK Profile